Lipidor and Cadila Pharmaceuticals partner on psoriasis product

1 June 2016
lipidor-large-1

Swedish dermatology specialist Lipidor and Cadila Pharmaceuticals, one of India’s largest privately-held pharma companies, have announced that they will collaborate on a Phase III trial and the joint commercialization of a psoriasis product.

The product concerned is a sprayable anti-psoriatic agent consisting of the generic vitamin D analogue, calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, Akvano.

The treatment is being developed for patients with mild to moderate psoriasis. Under the agreement, Cadila Pharmaceuticals will conduct a Phase III program in India, starting later this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical